LABORATORY NEWS
-
Invivoscribe Announces Updated Reimbursement For The LeukoStrat CDx FLT3 Mutation Assay To Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible For VANFLYTA In Japan
Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan's Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib).
- Oneoncology Presents Abstracts At ASCO Highlighting Importance Of Increasing NGS Testing
- IQVIA & (RED) Announce Groundbreaking Partnership To Support Laboratory System Strengthening
- Domus Diagnostics Moves Closer To Delivering Affordable At-Home Molecular Test For COVID-19, Flu-A, Flu-B And RSV
- Knobbe Martens Secures Complete Victory For Spectrum Solutions In Covid-19 Testing PTAB Dispute
ARCHIVED NEWSLETTER
- 05.23.23 -- 5 Characteristics Of The Automated Microbiology Lab Of The Future
- 05.09.23 -- Protecting Cell And Gene Therapy R&D Against Cyber Threats
- 04.25.23 -- Increase In FDA Inspections + Whistleblower Complaints = Heightened Compliance Scrutiny
- 04.11.23 -- ICH Guideline Q9(R1) On QRM, Part 1: Formality & Risk-based Decisions
- 03.28.23 -- Trends In FDA FY2022 Inspection-based Warning Letters
This website uses cookies to ensure you get the best experience on our website. Learn more